I just watched the video "Evolving Front-Line Therapy in Chronic Lymphocytic Leukemia" posted by EugeneL2. In it, she refers to the trial where patients on venetoclax + obinutuzumab had much better results than those on chlorambucil + obinutuzumab. However, she also noted that mutated patients on both treatments fared better than unmutated patients.
As an unmutated patient who decided to go with venetoclax over acalabrutinib I wonder about the unmutated factor. Don't unmutated patients do equally well on the BTK inhibitors?